Investor Updates - PDL BioPharma, Inc.
Aug 21, 2023 · The Investor Relations website contains information about PDL BioPharma, Inc.'s business for stockholders, potential investors, and financial analysts.
PDL BioPharma Reports 2020 Third Quarter Financial Results and …
Sep 30, 2020 · INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.
Jan 22, 2025 · PDL BioPharma, Inc. 59 Damonte Ranch Pkwy., Suite B-375 Reno, NV 89521 Tel: 775-832-8500 www.pdl.com January 22, 2025
Leadership | PDL BioPharma, Inc.
Mr. Monnet brings the Board of Directors of PDL BioPharma a strong understanding of the pharmaceutical and biotechnology industries and experience in the commercialization of pharmaceutical products.
Mar 5, 2024 · led suit against Eli Lilly and Company in the Southern District of Indiana in December of 2023. Our suit alleges anticipatory breach of contract by Eli Lilly and requests a declaratory judgment that Eli Lilly’s humanized antibody drug for treatment of Alzheimer’s Disease, donanemab, is a “Licensed Product” under the Development and ...
Common Stock Tax Information | PDL BioPharma, Inc.
May 13, 2022 · The Investor Relations website contains information about PDL BioPharma, Inc.'s business for stockholders, potential investors, and financial analysts.
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.
PDL BioPharma to Present at Jefferies 2014 Global Healthcare …
PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies.
PDL Announces Timeline for Voluntarily Delisting from Nasdaq
INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq").
PDL BioPharma Completes Quarterly Dividend Payment
Mar 4, 2016 · INCLINE VILLAGE, Nev., March 14, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning …